Abstract

MO27-3 Clinical outcomes of metastasis-directed radiation therapy (MDRT) for oligometastatic prostate cancer

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
The efficacy of metastasis-directed radiation therapy (MDRT) for oligometastatic castration-resistant prostate cancer (CRPC).
Tomohiro Kanaki ... Akira Nagahara
Journal of Clinical Oncology | VOL. 38
Tomohiro Kanaki, et. al.Tomohiro Kanaki ... Akira Nagahara
20 Feb 2020
Metastasis-directed therapy plus hormone therapy improves progression-free survival for advanced prostate cancer.
-
Cancer | VOL. 129
--
12 Dec 2022
Ultrahypofractionation Should be a Standard of Care Option for Intermediate-Risk Prostate Cancer
A Loblaw
Clinical Oncology | VOL. 32
A LoblawA Loblaw
28 Nov 2019
Fractionation Choice for Elective Lymph Node Radiation Therapy in Prostate Cancer: Slightly More to CHIRP About
Douglas H Brand ... Alison C Tree
International Journal of Radiation Oncology, Biology, Physics | VOL. 114
Douglas H Brand, et. al.Douglas H Brand ... Alison C Tree
14 Jul 2022
View more papers

More From: Annals of Oncology

Paper Title
Journal
Date
Author
Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: Final overall survival results of MONARCH 3
M.P Goetz ... S.R.D Johnston
Annals of Oncology | VOL. -
M.P Goetz, et. al.M.P Goetz ... S.R.D Johnston
01 May 2024
Overcoming barriers in biomarker testing. Letter to the Editor regarding: “ESMO study on the availability and accessibility of biomolecular technologies in oncology in Europe”, by A. Bayle et al.
J García-Foncillas ... A Stenzinger
Annals of Oncology | VOL. -
J García-Foncillas, et. al.J García-Foncillas ... A Stenzinger
01 May 2024
Table of Contents
-
Annals of Oncology | VOL. 35
--
01 May 2024
VP2-2024: Fuzuloparib with or without apatinib in HER2- metastatic breast cancer (mBC) patients (pts) with germline BRCA1/2 mutations (gBRCA1/2m): A randomized phase III trial
H Li ... E Song
Annals of Oncology | VOL. -
H Li, et. al.H Li ... E Song
01 May 2024
View more papers